Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial

JAMA Network Open
Takaki YoshikawaYuko Kitagawa

Abstract

Ramucirumab, a human IgG 1 antibody against vascular endothelial growth factor receptor 2, has been shown to improve progression-free survival and overall survival in patients with advanced gastric cancer in the second-line setting. To compare progression-free survival for S-1 and oxaliplatin plus ramucirumab with that for S-1 and oxaliplatin plus placebo in patients with advanced gastric cancer. This phase 2, double-blind randomized clinical trial (RAINSTORM [First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab in Patients With Advanced Gastric Cancer]) was conducted from October 12, 2015, to April 11, 2018, at 36 sites in Japan, South Korea, and Taiwan. Participants were chemotherapy-naive patients (n = 189) with metastatic gastric or gastroesophageal adenocarcinoma. Analyses of the full analysis set and safety population were conducted between November 27, 2017, and June 4, 2018. Patients randomized to the ramucirumab plus S-1 and oxaliplatin arm received S-1, 80 to 120 mg/d twice daily, on days 1 to 14 and oxaliplatin, 100 mg/m2, on day 1 with ramucirumab, 8 mg/kg, on days 1 and 8 in part A (21-day cycle). Patients randomized to the placebo plus S-1 and oxaliplatin arm received...Continue Reading

References

Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Atsushi OhtsuYoon-Koo Kang
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators
Feb 8, 2013·Angiogenesis·Guido BocciRomano Danesi
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Feb 22, 2014·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Lin ShenYongzhe Piao
Oct 16, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y YamadaI Hyodo
Jun 28, 2016·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·UNKNOWN Japanese Gastric Cancer Association
Oct 5, 2016·Journal of the National Comprehensive Cancer Network : JNCCN·Jaffer A AjaniHema Sundar
Jul 2, 2017·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Kohei ShitaraKei Muro
Jan 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y YamadaI Hyodo

❮ Previous
Next ❯

Citations

Aug 1, 2020·PloS One·Almudena Cotes SanchísAlberto Carmona-Bayonas
May 29, 2020·Technology in Cancer Research & Treatment·Boning XiaChang Liu
May 2, 2020·Cancers·Hiroyuki Arai, Takako Eguchi Nakajima
Mar 26, 2021·Advanced Healthcare Materials·Özlem ŞenGianni Ciofani
Jun 18, 2021·Indian Journal of Pathology & Microbiology·Satyajit Pawar, Atul Sharma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.